Rationale of Immunotherapy in Hepatocellular Carcinoma and Its Potential Biomarkers
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Rationale of Immunotherapy in Hepatocellular Carcinoma and Its Potential Biomarkers
Authors
Keywords
-
Journal
Cancers
Volume 11, Issue 12, Pages 1926
Publisher
MDPI AG
Online
2019-12-04
DOI
10.3390/cancers11121926
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Adoptive cell transfer therapy for hepatocellular carcinoma
- (2019) Renyu Zhang et al. Frontiers of Medicine
- Clinical implications of heterogeneity in PD-L1 immunohistochemical detection in hepatocellular carcinoma: the Blueprint-HCC study
- (2019) David J. Pinato et al. BRITISH JOURNAL OF CANCER
- Suppression of Exosomal PD-L1 Induces Systemic Anti-tumor Immunity and Memory
- (2019) Mauro Poggio et al. CELL
- Results of KEYNOTE-240: phase 3 study of pembrolizumab (Pembro) vs best supportive care (BSC) for second line therapy in advanced hepatocellular carcinoma (HCC).
- (2019) Richard S. Finn et al. JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab (NIVO) + ipilimumab (IPI) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Results from CheckMate 040.
- (2019) Thomas Yau et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase II study of anti–PD-1 antibody camrelizumab plus FOLFOX4 or GEMOX systemic chemotherapy as first-line therapy for advanced hepatocellular carcinoma or biliary tract cancer.
- (2019) Shukui Qin et al. JOURNAL OF CLINICAL ONCOLOGY
- First-line avelumab + axitinib in patients with advanced hepatocellular carcinoma: Results from a phase 1b trial (VEGF Liver 100).
- (2019) Masatoshi Kudo et al. JOURNAL OF CLINICAL ONCOLOGY
- Lenvatinib (len) plus pembrolizumab (pembro) for the first-line treatment of patients (pts) with advanced hepatocellular carcinoma (HCC): Phase 3 LEAP-002 study.
- (2019) Josep M Llovet et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase 3 (COSMIC-312) study of cabozantinib (C) in combination with atezolizumab (A) versus sorafenib (S) in patients (pts) with advanced hepatocellular carcinoma (aHCC) who have not received previous systemic anticancer therapy.
- (2019) Robin Kate Kelley et al. JOURNAL OF CLINICAL ONCOLOGY
- PD-1+ regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer
- (2019) Takahiro Kamada et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Optimizing radiotherapy with immune checkpoint blockade in hepatocellular carcinoma
- (2019) Changhoon Choi et al. WORLD JOURNAL OF GASTROENTEROLOGY
- Nivolumab in advanced hepatocellular carcinoma: Sorafenib-experienced Asian cohort analysis
- (2019) Thomas Yau et al. JOURNAL OF HEPATOLOGY
- Immunologic Correlates of Pathologic Complete Response to Preoperative Immunotherapy in Hepatocellular Carcinoma
- (2019) Ahmed Omar Kaseb et al. Cancer Immunology Research
- Dual PD ‐1 and VEGFR ‐2 blockade promotes vascular normalization and enhances anti‐tumor immune responses in HCC
- (2019) Kohei Shigeta et al. HEPATOLOGY
- Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers
- (2019) Aparna R. Parikh et al. NATURE MEDICINE
- LBA15_PRA phase III trial of empiric chemotherapy with cisplatin and gemcitabine or systemic treatment tailored by molecular gene expression analysis in patients with carcinomas of an unknown primary (CUP) site (GEFCAPI 04)
- (2019) K Fizazi et al. ANNALS OF ONCOLOGY
- LBA38_PRCheckMate 459: A randomized, multi-center phase III study of nivolumab (NIVO) vs sorafenib (SOR) as first-line (1L) treatment in patients (pts) with advanced hepatocellular carcinoma (aHCC)
- (2019) T Yau et al. ANNALS OF ONCOLOGY
- LBA3IMbrave150: Efficacy and safety results from a ph III study evaluating atezolizumab (atezo) + bevacizumab (bev) vs sorafenib (Sor) as first treatment (tx) for patients (pts) with unresectable hepatocellular carcinoma (HCC)
- (2019) A-L Cheng et al. ANNALS OF ONCOLOGY
- 325PAssociation between immune-related adverse events and efficacy of immune checkpoint inhibitors in patients with advanced hepatocellular carcinoma
- (2019) L Wong et al. ANNALS OF ONCOLOGY
- Tumor Cell Biodiversity Drives Microenvironmental Reprogramming in Liver Cancer
- (2019) Lichun Ma et al. CANCER CELL
- Pretreatment neutrophil-to-lymphocyte ratio is associated with outcome of advanced-stage cancer patients treated with immunotherapy: a meta-analysis
- (2018) Tao Jiang et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Association Between Pretreatment Neutrophil-to-Lymphocyte Ratio and Outcome of Patients With Metastatic Renal-Cell Carcinoma Treated With Nivolumab
- (2018) Mehmet Asim Bilen et al. Clinical Genitourinary Cancer
- Next generation natural killer cells for cancer immunotherapy: the promise of genetic engineering
- (2018) May Daher et al. CURRENT OPINION IN IMMUNOLOGY
- Collateral Damage: Insulin-Dependent Diabetes Induced With Checkpoint Inhibitors
- (2018) Angeliki M. Stamatouli et al. DIABETES
- Immune activation underlies a sustained clinical response to Yttrium-90 radioembolisation in hepatocellular carcinoma
- (2018) Valerie Chew et al. GUT
- Landscape of immune microenvironment in hepatocellular carcinoma and its additional impact on histological and molecular classification
- (2018) Yutaka Kurebayashi et al. HEPATOLOGY
- PD-L1 on host cells is essential for PD-L1 blockade–mediated tumor regression
- (2018) Haidong Tang et al. JOURNAL OF CLINICAL INVESTIGATION
- Sex and interleukin-6 are prognostic factors for autoimmune toxicity following treatment with anti-CTLA4 blockade
- (2018) Sara Valpione et al. Journal of Translational Medicine
- Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
- (2018) Andrew X Zhu et al. LANCET ONCOLOGY
- Targeting tumour microenvironment by tyrosine kinase inhibitor
- (2018) Hor-Yue Tan et al. Molecular Cancer
- A transcriptionally and functionally distinct PD-1+ CD8+ T cell pool with predictive potential in non-small-cell lung cancer treated with PD-1 blockade
- (2018) Daniela S. Thommen et al. NATURE MEDICINE
- High-dimensional single-cell analysis predicts response to anti-PD-1 immunotherapy
- (2018) Carsten Krieg et al. NATURE MEDICINE
- Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden
- (2018) Matthew D. Hellmann et al. NEW ENGLAND JOURNAL OF MEDICINE
- Neoadjuvant PD-1 Blockade in Resectable Lung Cancer
- (2018) Patrick M. Forde et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clinical significance of soluble programmed cell death ligand-1 (sPD-L1) in hepatocellular carcinoma patients treated with radiotherapy
- (2018) Hyun Ju Kim et al. RADIOTHERAPY AND ONCOLOGY
- The commensal microbiome is associated with anti–PD-1 efficacy in metastatic melanoma patients
- (2018) Vyara Matson et al. SCIENCE
- The microbiome in cancer immunotherapy: Diagnostic tools and therapeutic strategies
- (2018) Laurence Zitvogel et al. SCIENCE
- T cell–induced CSF1 promotes melanoma resistance to PD1 blockade
- (2018) Natalie J. Neubert et al. Science Translational Medicine
- Current status and future directions of cancer immunotherapy
- (2018) Hongming Zhang et al. Journal of Cancer
- Regulation of PD-L1: Emerging Routes for Targeting Tumor Immune Evasion
- (2018) Yiting Wang et al. Frontiers in Pharmacology
- Alpha-Fetoprotein and Hepatocellular Carcinoma Immunity
- (2018) Xiaoping Wang et al. Canadian Journal of Gastroenterology and Hepatology
- Biomarkers for Clinical Benefit of Immune Checkpoint Inhibitor Treatment—A Review From the Melanoma Perspective and Beyond
- (2018) Kristina Buder-Bakhaya et al. Frontiers in Immunology
- Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non–Small Cell Lung Cancer
- (2018) Laura Mezquita et al. JAMA Oncology
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2018) Freddie Bray et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Targeting PD-L1 protein: translation, modification and transport
- (2018) Ran Wei et al. CURRENT PROTEIN & PEPTIDE SCIENCE
- A multicenter pilot study of nivolumab (NIVO) with drug eluting bead transarterial chemoembolization (deb-TACE) in patients (pts) with liver limited hepatocellular carcinoma (HCC).
- (2018) James J. Harding et al. JOURNAL OF CLINICAL ONCOLOGY
- A randomized, multicenter phase 3 study of durvalumab (D) and tremelimumab (T) as first-line treatment in patients with unresectable hepatocellular carcinoma (HCC): HIMALAYA study.
- (2018) Ghassan K. Abou-Alfa et al. JOURNAL OF CLINICAL ONCOLOGY
- Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response
- (2018) Gang Chen et al. NATURE
- TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
- (2018) Sanjeev Mariathasan et al. NATURE
- Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab
- (2018) David R. Gandara et al. NATURE MEDICINE
- Fundamental Mechanisms of Immune Checkpoint Blockade Therapy
- (2018) Spencer C. Wei et al. Cancer Discovery
- Natural Killer Cells in Liver Disease and Hepatocellular Carcinoma and the NK Cell-Based Immunotherapy
- (2018) Pingyi Liu et al. Journal of Immunology Research
- Defining T Cell States Associated with Response to Checkpoint Immunotherapy in Melanoma
- (2018) Moshe Sade-Feldman et al. CELL
- Prospective Genotyping of Hepatocellular Carcinoma: Clinical Implications of Next Generation Sequencing for Matching Patients to Targeted and Immune Therapies
- (2018) James J Harding et al. CLINICAL CANCER RESEARCH
- Association Between Expression Level of PD1 by Tumor-Infiltrating CD8+ T Cells and Features of Hepatocellular Carcinoma
- (2018) Hyung-Don Kim et al. GASTROENTEROLOGY
- Autoantibody Development under Treatment with Immune-Checkpoint Inhibitors
- (2018) Emma C. de Moel et al. Cancer Immunology Research
- Identification of an Immune-specific Class of Hepatocellular Carcinoma, Based on Molecular Features
- (2017) Daniela Sia et al. GASTROENTEROLOGY
- The Roles of microRNAs in Regulating the Expression of PD-1/PD-L1 Immune Checkpoint
- (2017) Qingshui Wang et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
- (2017) Mark Ayers et al. JOURNAL OF CLINICAL INVESTIGATION
- Fluctuations in routine blood count might signal severe immune-related adverse events in melanoma patients treated with nivolumab
- (2017) Yasuhiro Fujisawa et al. JOURNAL OF DERMATOLOGICAL SCIENCE
- Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma
- (2017) Austin G. Duffy et al. JOURNAL OF HEPATOLOGY
- Early Immune-Related Adverse Events and Association with Outcome in Advanced Non–Small Cell Lung Cancer Patients Treated with Nivolumab: A Prospective Cohort Study
- (2017) Shunsuke Teraoka et al. Journal of Thoracic Oncology
- Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
- (2017) Anthony B El-Khoueiry et al. LANCET
- Pretreatment neutrophil-to-lymphocyte ratio as a marker of outcomes in nivolumab-treated patients with advanced non-small-cell lung cancer
- (2017) Stephen J. Bagley et al. LUNG CANCER
- Oncolytic Virus-Based Immunotherapies for Hepatocellular Carcinoma
- (2017) So Young Yoo et al. MEDIATORS OF INFLAMMATION
- Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers
- (2017) Aaron M. Goodman et al. MOLECULAR CANCER THERAPEUTICS
- Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer
- (2017) Ugur Sahin et al. NATURE
- T-cell invigoration to tumour burden ratio associated with anti-PD-1 response
- (2017) Alexander C. Huang et al. NATURE
- CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity
- (2017) Marian L. Burr et al. NATURE
- An immunogenic personal neoantigen vaccine for patients with melanoma
- (2017) Patrick A. Ott et al. NATURE
- Monitoring immune-checkpoint blockade: response evaluation and biomarker development
- (2017) Mizuki Nishino et al. Nature Reviews Clinical Oncology
- Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
- (2017) Jedd D. Wolchok et al. NEW ENGLAND JOURNAL OF MEDICINE
- First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer
- (2017) David P. Carbone et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tumor Mutational Burden and Response Rate to PD-1 Inhibition
- (2017) Mark Yarchoan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immune‐Related Adverse Events as a Biomarker in Non‐Melanoma Patients Treated with Programmed Cell Death 1 Inhibitors
- (2017) Julia Judd et al. ONCOLOGIST
- Delineation of an immunosuppressive gradient in hepatocellular carcinoma using high-dimensional proteomic and transcriptomic analyses
- (2017) Valerie Chew et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
- (2017) Dung T. Le et al. SCIENCE
- Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy
- (2017) Diego Chowell et al. SCIENCE
- Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients
- (2017) V. Gopalakrishnan et al. SCIENCE
- Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors
- (2017) Bertrand Routy et al. SCIENCE
- The spatial organization of intra-tumour heterogeneity and evolutionary trajectories of metastases in hepatocellular carcinoma
- (2017) Weiwei Zhai et al. Nature Communications
- Relationships between lymphocyte counts and treatment-related toxicities and clinical responses in patients with solid tumors treated with PD-1 checkpoint inhibitors
- (2017) Adam Diehl et al. Oncotarget
- Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression
- (2017) Angel Garcia-Diaz et al. Cell Reports
- Pan-cancer Immunogenomic Analyses Reveal Genotype-Immunophenotype Relationships and Predictors of Response to Checkpoint Blockade
- (2017) Pornpimol Charoentong et al. Cell Reports
- Development of thyroid dysfunction is associated with clinical response to PD-1 blockade treatment in patients with advanced non-small cell lung cancer
- (2017) Hye In Kim et al. OncoImmunology
- Oncolytic Viruses—Natural and Genetically Engineered Cancer Immunotherapies
- (2017) Sachin R. Jhawar et al. Frontiers in Oncology
- Oncolytic Viruses—Interaction of Virus and Tumor Cells in the Battle to Eliminate Cancer
- (2017) Anwen Howells et al. Frontiers in Oncology
- CTLA-4 and PD-1 Pathways
- (2016) Elizabeth I. Buchbinder et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- Microbiome and Anticancer Immunosurveillance
- (2016) Laurence Zitvogel et al. CELL
- Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab
- (2016) Benjamin Weide et al. CLINICAL CANCER RESEARCH
- Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab
- (2016) A. Martens et al. CLINICAL CANCER RESEARCH
- Clinical Significance of Circulating CD33+CD11b+HLA-DR- Myeloid Cells in Patients with Stage IV Melanoma Treated with Ipilimumab
- (2016) M. Sade-Feldman et al. CLINICAL CANCER RESEARCH
- Variable Intra-Tumor Genomic Heterogeneity of Multiple Lesions in Patients With Hepatocellular Carcinoma
- (2016) Ruidong Xue et al. GASTROENTEROLOGY
- Use of LDH and autoimmune side effects to predict response to ipilimumab treatment
- (2016) J Dick et al. Immunotherapy
- Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
- (2016) Jonathan E Rosenberg et al. LANCET
- Predictive biomarkers for checkpoint inhibitor-based immunotherapy
- (2016) Geoffrey T Gibney et al. LANCET ONCOLOGY
- Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
- (2016) Robert L. Ferris et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
- (2016) Martin Reck et al. NEW ENGLAND JOURNAL OF MEDICINE
- Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade
- (2016) P.-L. Chen et al. Cancer Discovery
- Intratumoral CD3 and CD8 T-cell Densities Associated with Relapse-Free Survival in HCC
- (2016) A. Gabrielson et al. Cancer Immunology Research
- Intratumoral expression levels of PD-L1, GZMA, and HLA-A along with oligoclonal T cell expansion associate with response to nivolumab in metastatic melanoma
- (2016) Hiroyuki Inoue et al. OncoImmunology
- IFN-γ from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer
- (2015) K Abiko et al. BRITISH JOURNAL OF CANCER
- Baseline neutrophil-to-lymphocyte ratio is associated with outcome of ipilimumab-treated metastatic melanoma patients
- (2015) P F Ferrucci et al. BRITISH JOURNAL OF CANCER
- Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents
- (2015) Lorenzo Galluzzi et al. CANCER CELL
- Nivolumab in Resected and Unresectable Metastatic Melanoma: Characteristics of Immune-Related Adverse Events and Association with Outcomes
- (2015) M. Freeman-Keller et al. CLINICAL CANCER RESEARCH
- Myeloid Cells and Related Chronic Inflammatory Factors as Novel Predictive Markers in Melanoma Treatment with Ipilimumab
- (2015) C. Gebhardt et al. CLINICAL CANCER RESEARCH
- Vitiligo-Like Depigmentation in Patients With Stage III-IV Melanoma Receiving Immunotherapy and Its Association With Survival: A Systematic Review and Meta-Analysis
- (2015) Hansje-Eva Teulings et al. JOURNAL OF CLINICAL ONCOLOGY
- Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center
- (2015) Troy Z. Horvat et al. JOURNAL OF CLINICAL ONCOLOGY
- Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity
- (2015) Stefani Spranger et al. NATURE
- Oncolytic viruses: a new class of immunotherapy drugs
- (2015) Howard L. Kaufman et al. NATURE REVIEWS DRUG DISCOVERY
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Hossein Borghaei et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
- (2015) Robert J. Motzer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cancer and the microbiota
- (2015) W. S. Garrett SCIENCE
- Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
- (2015) N. A. Rizvi et al. SCIENCE
- Radiotherapy and Immunogenic Cell Death
- (2015) Encouse B. Golden et al. SEMINARS IN RADIATION ONCOLOGY
- A randomized controlled trial on patients with or without adjuvant autologous cytokine-induced killer cells after curative resection for hepatocellular carcinoma
- (2015) Li Xu et al. OncoImmunology
- Peripheral T cell receptor diversity is associated with clinical outcomes following ipilimumab treatment in metastatic melanoma
- (2015) Michael A. Postow et al. Journal for ImmunoTherapy of Cancer
- The role of LDH serum levels in predicting global outcome in HCC patients treated with sorafenib: implications for clinical management
- (2014) Luca Faloppi et al. BMC CANCER
- Antiangiogenesis Strategies Revisited: From Starving Tumors to Alleviating Hypoxia
- (2014) Rakesh K. Jain CANCER CELL
- Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma
- (2014) Sander Kelderman et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma
- (2014) Ester Simeone et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
- (2014) Roy S. Herbst et al. NATURE
- PD-1 blockade induces responses by inhibiting adaptive immune resistance
- (2014) Paul C. Tumeh et al. NATURE
- Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
- (2014) Alexandra Snyder et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immune Monitoring of the Circulation and the Tumor Microenvironment in Patients with Regionally Advanced Melanoma Receiving Neoadjuvant Ipilimumab
- (2014) Ahmad A. Tarhini et al. PLoS One
- Improved Survival with T Cell Clonotype Stability After Anti-CTLA-4 Treatment in Cancer Patients
- (2014) E. Cha et al. Science Translational Medicine
- Mechanism of Action of Immunotherapy
- (2014) Mary L. Disis SEMINARS IN ONCOLOGY
- Blood-Based Analyses of Cancer: Circulating Tumor Cells and Circulating Tumor DNA
- (2014) D. A. Haber et al. Cancer Discovery
- Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab
- (2013) Christiane Meyer et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Immune Infiltrates Are Prognostic Factors in Localized Gastrointestinal Stromal Tumors
- (2013) S. Rusakiewicz et al. CANCER RESEARCH
- Lactate dehydrogenase a in cancer: A promising target for diagnosis and therapy
- (2013) Ping Miao et al. IUBMB LIFE
- A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C
- (2013) Bruno Sangro et al. JOURNAL OF HEPATOLOGY
- Challenges in cancer vaccine development for hepatocellular carcinoma
- (2013) Luigi Buonaguro et al. JOURNAL OF HEPATOLOGY
- Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer
- (2013) Jeong Heo et al. NATURE MEDICINE
- Cancer Immunotherapy
- (2013) J. Couzin-Frankel SCIENCE
- Up-Regulation of PD-L1, IDO, and Tregs in the Melanoma Tumor Microenvironment Is Driven by CD8+ T Cells
- (2013) S. Spranger et al. Science Translational Medicine
- Vascular Normalization as a Therapeutic Strategy for Malignant and Nonmalignant Disease
- (2013) S. Goel et al. Cold Spring Harbor Perspectives in Medicine
- Immunogenic Cell Death in Cancer Therapy
- (2012) Guido Kroemer et al. Annual Review of Immunology
- Neuropilin 1 deficiency on CD4+Foxp3+regulatory T cells impairs mouse melanoma growth
- (2012) Wiebke Hansen et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Sorafenib reduces hepatic infiltrated regulatory T cells in hepatocellular carcinoma patients by suppressing TGF-beta signal
- (2012) Quanrongzi Wang et al. JOURNAL OF SURGICAL ONCOLOGY
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Role of LDH Serum Levels in Predicting Global Outcome in HCC Patients Undergoing TACE: Implications for Clinical Management
- (2012) Mario Scartozzi et al. PLoS One
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- Chemokine-driven lymphocyte infiltration: an early intratumoural event determining long-term survival in resectable hepatocellular carcinoma
- (2011) Valerie Chew et al. GUT
- Antiangiogenic Agents Can Increase Lymphocyte Infiltration into Tumor and Enhance the Effectiveness of Adoptive Immunotherapy of Cancer
- (2010) R. K. Shrimali et al. CANCER RESEARCH
- Direct and Differential Suppression of Myeloid-Derived Suppressor Cell Subsets by Sunitinib Is Compartmentally Constrained
- (2010) Jennifer S. Ko et al. CANCER RESEARCH
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Etiology of Hepatocellular Carcinoma and Consequences for Treatment
- (2010) A. J. Sanyal et al. ONCOLOGIST
- The Novel Role of Tyrosine Kinase Inhibitor in the Reversal of Immune Suppression and Modulation of Tumor Microenvironment for Immune-Based Cancer Therapies
- (2009) J. Ozao-Choy et al. CANCER RESEARCH
- Sunitinib Inhibition of Stat3 Induces Renal Cell Carcinoma Tumor Cell Apoptosis and Reduces Immunosuppressive Cells
- (2009) H. Xin et al. CANCER RESEARCH
- Overexpression of PD-L1 Significantly Associates with Tumor Aggressiveness and Postoperative Recurrence in Human Hepatocellular Carcinoma
- (2009) Q. Gao et al. CLINICAL CANCER RESEARCH
- Profile of Tumor Antigen-Specific CD8 T Cells in Patients With Hepatitis B Virus-Related Hepatocellular Carcinoma
- (2009) Adam J. Gehring et al. GASTROENTEROLOGY
- Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1
- (2009) Dong-Ming Kuang et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Inflammatory tumour microenvironment is associated with superior survival in hepatocellular carcinoma patients
- (2009) Valerie Chew et al. JOURNAL OF HEPATOLOGY
- Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy
- (2009) S Mustjoki et al. LEUKEMIA
- Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial
- (2008) Byeong-Ho Park et al. LANCET ONCOLOGY
- Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling
- (2008) Scott M. Wilhelm et al. MOLECULAR CANCER THERAPEUTICS
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. NEW ENGLAND JOURNAL OF MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started